Tarlatamab plus durvalumab cuts death risk 58% in first-line small cell lung cancer, extending median overall survival to ...

RELATIVITY-047's 5-year survival data and LAG-3-high CD8+ T cell biomarker findings signal a shift in how immuno-oncology ...

NHWD-870 HCl achieves 45% response rate in thoracic NUT carcinoma, nearly doubling the overall cohort's 30% rate in advanced ...

ASP-1929 + Pembrolizumab achieved 28.2-month median OS in recurrent/metastatic HNSCC, with 35% alive at four years in Phase ...

FDA AI Guidance requires clinical trial sponsors to validate algorithms before submission, shifting documentation and testing ...

A Nature Neuroscience study separates psilocybin's neuroplastic effects from its hallucinogenic ones, and it should reshape ...

Lilly's sofetabart mipitecan achieves 79% response rate in platinum-sensitive ovarian cancer patients, including those with prior PARP inhibitor exposure.

WCG's Activation Intelligence targets clinical trial rework by catching document conflicts before activation, saving sites ...

Clinical Solutions appoints three C-suite executives to lead product, finance, and talent functions amid strong first-half ...

MA beneficiaries received kidney transplants at nearly half the rate of traditional Medicare patients post-Cures Act, a ...

Tango Therapeutics updates vopimetostat Phase 1/2 Trial results in combination with RAS(ON) inhibitors. Full data available in SEC filing.

Upacicalcet meets primary endpoints in Phase 3 trials for secondary hyperparathyroidism, with 42–44% of patients achieving 30% PTH reduction versus 17% on place ...